The blockade of PD-1/PD-L1 interaction using monoclonal antibodies has been approved by the US Food and Drug Administration (FDA) as an effective therapy for several solid tumors and further approved in Hodgkin lymphoma as the first hematological indication, and the significance of PD-1/PD-L1 blockade in TCL therapeutic strategy is still unclear. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.